St. Jude has played a key role in vector development, pioneering innovative vector designs for patients with hemophilia and
the devastating immune disorder X-linked severe combined immunodeficiency (SCID).
Not exact matches
Infections can trigger
immune attacks on kids» brains, provoking
devastating psychiatric
disorders.
«These results are an exciting early indication that this gene therapy is well tolerated and effective in infants as young as 2 months old with this
devastating inherited
immune disorder,» said Ewelina Mamcarz, M.D., an assistant member of the St. Jude Department of Bone Marrow Transplantation and Cellular Therapy.
Preliminary findings indicate gene therapy pioneered at St. Jude Children's Research Hospital is safe and effective for babies with a
devastating inherited
disorder that leaves them with little or no
immune protection